Sources of Interindividual Variability
Authors:
- 17 July 2021
- book chapter
- Published by Springer Nature
- Vol. 2342, 481-550
Abstract
The efficacy, safety, and tolerability of drugs are dependent on numerous factors that influence their disposition. A dose that is efficacious and safe for one individual may result in sub-therapeutic or toxic blood concentrations in others. A significant source of this variability in drug response is drug metabolism, where differences in presystemic and systemic biotransformation efficiency result in variable degrees of systemic exposure (e.g., AUC, Cmax, and/or Cmin) following administration of a fixed dose. Interindividual differences in drug biotransformation have been studied extensively. It is recognized that both intrinsic factors (e.g., genetics, age, sex, and disease states) and extrinsic factors (e.g., diet, chemical exposures from the environment, and the microbiome) play a significant role. For drug-metabolizing enzymes, genetic variation can result in the complete absence or enhanced expression of a functional enzyme. In addition, upregulation and downregulation of gene expression, in response to an altered cellular environment, can achieve the same range of metabolic function (phenotype), but often in a less predictable and time-dependent manner. Understanding the mechanistic basis for variability in drug disposition and response is essential if we are to move beyond the era of empirical, trial-and-error dose selection and into an age of personalized medicine that will improve outcomes in maintaining health and treating disease.Keywords
This publication has 490 references indexed in Scilit:
- Compartment-Specific Gene Regulation of the CAR Inducer Efavirenz In VivoClinical Pharmacology & Therapeutics, 2012
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) GenotypeClinical Pharmacology & Therapeutics, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin DosingClinical Pharmacology & Therapeutics, 2011
- Pharmacokinetics of oseltamivir among pregnant and nonpregnant womenAmerican Journal of Obstetrics and Gynecology, 2011
- Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemiaPediatric Blood & Cancer, 2010
- Variability in drug metabolizing enzyme activity in HIV-infected patientsEuropean Journal of Clinical Pharmacology, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis for Better Clinical PracticeClinical Pharmacology & Therapeutics, 2009
- Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and PharmacokineticsClinical Pharmacology & Therapeutics, 2009
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006